| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Respiratory System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Respiratory System | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Respiratory System |
Recent Updates
Recently added Catalysts
Celldex Therapeutics, Inc.$35.74
+0.02 (+0.06%)
C 59Pipeline Score Fair Value Biotech · Clinical
Market Cap
2.41 B
EPS
-4.27
P/E Ratio
-
Value Trade
25.78 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
15.00 K
R&D Expenses
73.00 M
Operating CF
-65.59 M
Total Assets
511.25 M
Total Liabilities
55.03 M
Equity
456.23 M
D/E Ratio
12,345
-4.18 %
Week
-11.11 %
1 Month
31.66 %
3 Month
23.27 %
6 Month
9.75 %
5 Year
-96.5 %
All Time
Cash Data
Cash Position
451.46 M
Monthly Burn
21.86 M
Runway
17.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
8.93 K
52 Week Range
18.55 - 35.79
% held by Insiders
2.83 %
% held by Institutions
91.81 %
Enterprise Value
1.97 B
Total Shares
78.53 M
Short %
10.81 %
Float Shares
70.91 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Celldex Therapeutics, Inc.
996Total events
5Upcoming
171Tier-1 (high impact)
2008 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▼Topline ReadoutBarzolvolimabFiledClinical Data
Subscribe to view catalyst details
TBD
▼Trial DiscontinuedBarzolvolimabFiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-14 | CDX-622 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-14 | CDX-622 | Phase 1 data readout | Phase 1 | — | – | – | – |
2026-06-14 | CDX-622 | Phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
C59
Pipeline Score $3.2B
Pipeline ValueFair Value
Valuation Signal25
Drugs Scored1.3x
rNPV / MCap Top 89%
Small Cap (rank 101 of 913)
Percentile RankCelldex Therapeutics, Inc. carries a moderate pipeline score (59/100), with $5.4B risk-adjusted pipeline value, led by Barzolvolimab in Atopic Dermatitis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| barzolvolimab Monoclonal antibody | Chronic Spontaneous Urticaria | Phase 3 | NCT06445023 | 68% | $791M | ACTIVE NOT_RECRUITING | 3,517 | VERY_FAST | B (69) | Apr 1, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
barzolvolimab | prurigo nodularis | Phase 2 | 2026-07-21 | The study did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.; Percentage of patients with at least 4 point improvement in WI-NRS did not differentiate from placebo.; Percentage of patients with IGA-CPNG-S 0/1 did not differentiate from placebo.; No improvement observed with longer treatment (Week 24). Read More | Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis Read More | |
barzolvolimab | prurigo nodularis | Phase 2 | 2026-07-21 | The study did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.; Percentage of patients with at least 4 point improvement in WI-NRS did not differentiate from placebo.; Percentage of patients with IGA-CPNG-S 0/1 did not differentiate from placebo.; No improvement observed with longer treatment (Week 24). Read More | Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis Read More | |
barzolvolimab | prurigo nodularis | Phase 2 | 2026-07-21 | The study did not meet primary or key secondary endpoints at Week 12 at either dose level evaluated.; Percentage of patients with at least 4 point improvement in WI-NRS did not differentiate from placebo.; Percentage of patients with IGA-CPNG-S 0/1 did not differentiate from placebo.; No improvement observed with longer treatment (Week 24). Read More | Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CLDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CLDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CLDXCelldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex's Phase 2 study of barzolvolimab in prurigo nodularis did not meet its primary or key secondary endpoints, leading to the discontinuation of the study. Despite showing a favorable safety profile and significant mast cell depletion, the treatment failed to improve symptoms compared to placebo. The company remains focused on other indications where barzolvolimab has shown promise.
Read more →CLDX▼ -7.6%on this newsshared move
Celldex Announces Planned Transition of Chief Financial Officer
Celldex announced the planned retirement of CFO Sam Martin in 2027 after serving since 2017. The company is searching for a new CFO while ensuring a smooth transition. Martin expressed pride in the company's achievements and confidence in its future, particularly with upcoming Phase 3 trial data for barzolvolimab.
Read more →CLDXCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented long-term results from a Phase 2 study of barzolvolimab at the EAACI Annual Meeting, showing significant and sustained improvements in angioedema for patients with chronic spontaneous urticaria (CSU). Seven months after treatment, 64% of patients remained angioedema-free. The findings support ongoing Phase 3 trials, with topline data expected in Q4 2026.
Read more →CLDXCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Celldex presented positive Phase 1 results for CDX-622, a bispecific antibody targeting soluble SCF and TSLP, at the EAACI Annual Meeting. The study showed significant reductions in serum tryptase, indicating effective mast cell depletion, and was well-tolerated across all doses. The findings suggest a promising avenue for treating inflammatory diseases.
Read more →CLDXCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
Celldex announced three upcoming presentations at the EAACI Annual Congress in Istanbul, showcasing their mast cell targeting pipeline. The presentations will include results from the barzolvolimab program in chronic spontaneous urticaria and a late-breaking poster on the bispecific antibody CDX-622. These findings highlight the potential of these therapies in treating inflammatory conditions.
Read more →CLDXCelldex Reports First Quarter Financial Results and Provides Corporate Update
Celldex (NASDAQ: CLDX) reported its first quarter financial results for 2026, highlighting the early completion of enrollment in two Phase 3 studies for barzolvolimab. The company raised $345 million from a public offering and is anticipating multiple data readouts in 2026, indicating strong potential for its pipeline. Despite these positive developments, Celldex experienced an increase in net loss and a significant drop in revenue compared to the previous year. The company remains focused on advancing its clinical programs and preparing for commercialization.
Read more →CLDXCelldex to Present at Upcoming April 2026 Investor Conference
Celldex (NASDAQ:CLDX) will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026. The event will be accessible via webcast, with replays available for 90 days. This participation highlights Celldex's commitment to engaging with investors and discussing its advancements in immunology.
Read more →CLDXCelldex to Present at Upcoming Investor Conference
Celldex (NASDAQ:CLDX) will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026. The event will be accessible via webcast, with replays available for 90 days. This engagement highlights Celldex's commitment to advancing immunology therapies.
Read more →CLDXCelldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Celldex Therapeutics has completed its public offering of 11,896,750 shares of common stock, raising around $345 million in gross proceeds. This offering included full exercise of the underwriters' option for an additional 1,551,750 shares, reflecting strong market interest. All shares were sold by Celldex, utilizing a previously filed registration statement with the SEC. The successful closure of this offering is expected to bolster the company's finances as it advances its therapeutic pipeline.
Read more →CLDXCelldex Announces Pricing of $300 Million Public Offering of Common Stock
Celldex Therapeutics has announced a public offering of 10,345,000 shares at $29.00 each, aiming to raise approximately $300 million. The proceeds will support ongoing commercial activities for barzolvolimab and further development of its product candidates. The offering is expected to close around April 6, 2026, pending customary conditions.
Read more →CLDXCelldex Announces Proposed Public Offering of Common Stock
Celldex Therapeutics has announced a proposed public offering of its common stock to fund various initiatives, including the commercial launch of barzolvolimab for CSU treatment. The offering includes a 30-day option for underwriters to purchase additional shares. The final terms will be determined by market conditions, with no guarantees on completion.
Read more →CLDXCelldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
Celldex presented positive Phase 2 trial data for barzolvolimab, showing significant improvements in quality of life for patients with chronic spontaneous urticaria and cold urticaria. The findings were shared at the AAD Annual Meeting, highlighting the drug's unique mechanism targeting mast cells. The company is advancing to Phase 3 trials, with expectations for topline data by late 2026.
Read more →CLDXCelldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex presented positive Phase 2 data at the AAAAI 2026, demonstrating that retreatment with barzolvolimab leads to rapid improvement in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD). The study highlighted that patients can achieve similar efficacy upon retreatment as seen in initial treatments. Barzolvolimab's unique mechanism targets mast cells, making it a promising option for chronic urticaria.
Read more →CLDXCelldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex has presented promising data from Phase 2 trials of barzolvolimab for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the AAAAI Annual Meeting. The results indicate sustained efficacy even after treatment cessation, alongside improved patient quality of life. Barzolvolimab's unique mechanism targets mast cells, potentially transforming treatment options for these conditions.
Read more →CLDXCelldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Celldex reported its financial results for Q4 and the year ending December 31, 2025, highlighting strong progress in its clinical programs, particularly for barzolvolimab. The company completed enrollment in its Phase 3 CSU studies ahead of schedule and anticipates multiple important data readouts in 2026. However, it also reported a significant net loss and a decrease in revenue compared to the previous year.
Read more →CLDX▲ +24.1%on this newsshared move
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
Celldex has completed enrollment in its global Phase 3 studies of barzolvolimab for chronic spontaneous urticaria, with 1,939 patients enrolled across 43 countries. The studies aim to establish the efficacy and safety of barzolvolimab in patients unresponsive to antihistamines. Results are expected later this year, highlighting the treatment's potential to address significant unmet needs in CSU.
Read more →CLDX▲ +5.6%on this news· ran to +33% by day 3shared move
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
Celldex announced that multiple presentations regarding barzolvolimab's Phase 2 trials will be showcased at the AAAAI 2026 Annual Meeting. The data highlights the drug's effectiveness in managing chronic spontaneous urticaria and related conditions. Barzolvolimab is being studied for its potential as a first-in-class treatment, with ongoing Phase 3 trials planned.
Read more →CLDXCelldex to Present at Upcoming Investor Conferences
Celldex (NASDAQ:CLDX) has announced its participation in upcoming investor conferences, where management will engage in fireside chats. Live webcasts of these presentations will be available on the company's website, and replays will be accessible for 90 days post-event. This initiative reflects Celldex's commitment to investor engagement and transparency.
Read more →CLDX▼ -5.7%on this news
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
Celldex has launched a global Phase 3 trial for barzolvolimab, targeting adult patients suffering from cold urticaria (ColdU) and symptomatic dermographism (SD). This program aims to establish the efficacy and safety of the drug, which has previously demonstrated significant benefits in prior studies. As there are currently no approved therapies for these conditions, this trial is a critical step in providing new treatment options for affected individuals. The study will recruit approximately 240 participants from about 75 clinical trial sites across seven countries.
Read more →CLDX▲ +7.5%on this news
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Celldex reported its Q3 2025 financial results, highlighting advancements in mast cell biology and the promising performance of barzolvolimab. The company is preparing for potential commercialization and has appointed Teri Lawver as Senior VP for Commercialization. Despite a notable net loss and decreased revenue, Celldex remains optimistic about its pipeline and future data readouts.
Read more →CLDXCelldex Announces Appointment of Teri Lawver as Chief Commercial Officer
Celldex has appointed Teri Lawver as the new Chief Commercial Officer, succeeding Richard Wright. Lawver, a seasoned executive with 30 years of experience, is expected to leverage her background in immunology to drive the company's commercial strategy, particularly in anticipation of the barzolvolimab launch. Wright's retirement marks the end of over a decade of leadership at Celldex.
Read more →CLDXCelldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20
Celldex has presented positive results from its Phase 2 study of barzolvolimab for cold urticaria and symptomatic dermographism, demonstrating sustained efficacy and a favorable safety profile over a 20-week treatment period. The study showed that up to 66% of patients with cold urticaria and 49% with symptomatic dermographism achieved a complete response. Celldex plans to initiate a Phase 3 study next month, marking a significant advancement for patients lacking approved treatments.
Read more →CLDXCelldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
Celldex has presented additional positive data on barzolvolimab's effectiveness in achieving rapid and durable control of chronic spontaneous urticaria (CSU) at the ACAAI Annual Scientific Meeting. The Phase 2 study demonstrated significant improvements in urticaria control, with many patients reporting complete responses even after treatment cessation. The company is now enrolling patients for a global Phase 3 program to further evaluate barzolvolimab's efficacy and safety.
Read more →CLDXCelldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
Celldex announced positive results from its Phase 1 trial of CDX-622, a bispecific antibody targeting pathways involved in inflammation. The study showed that CDX-622 was well tolerated and effectively reduced serum tryptase levels, indicating mast cell inhibition. The company plans to advance to a Phase 1b study in asthma patients, aiming to assess the dual neutralization effects of CDX-622.
Read more →CLDXCelldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Celldex has presented promising Phase 2 data for barzolvolimab, demonstrating its efficacy in treating chronic spontaneous urticaria (CSU) regardless of baseline immunoglobulin E levels. The study showed significant improvements in UAS7 scores and a well-tolerated safety profile. The company is now enrolling patients for a global Phase 3 program to further evaluate the treatment's efficacy and safety.
Read more →CLDXCelldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
Celldex Therapeutics, Inc. will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The event is scheduled for 3:20 pm ET, and a live webcast will be available on their website. A replay will be accessible for 90 days post-event.
Read more →CLDX▼ -13%on this news
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
Celldex Therapeutics announced topline results from its Phase 2 study of barzolvolimab for eosinophilic esophagitis (EoE). While the study met its primary endpoint of mast cell depletion, it did not show improvement in EoE symptoms compared to placebo. Consequently, Celldex will discontinue development in EoE but will continue exploring other indications for barzolvolimab.
Read more →CLDXCelldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Celldex Therapeutics reported strong progress in its Phase 2 studies of barzolvolimab, demonstrating profound clinical benefits and improved quality of life for patients with chronic spontaneous urticaria. Despite a significant net loss and decreased revenues for the second quarter of 2025, the company is focused on advancing its clinical programs and has a solid cash position projected to support operations through 2027. Upcoming data readouts are expected to further bolster its pipeline and ongoing clinical trials.
Read more →CLDXCelldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Celldex Therapeutics presented promising data at the EAACI Congress 2025, showcasing that 77% of patients treated with barzolvolimab for chronic spontaneous urticaria (CSU) were angioedema-free after 52 weeks. The Phase 2 clinical trial further demonstrated rapid and durable improvements in angioedema symptoms and quality of life metrics among participants. The drug met its primary and secondary endpoints, indicating a significant clinical benefit. The safety profile of barzolvolimab remained favorable throughout the study.
Read more →CLDXCelldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Celldex has presented promising 76-week results from their Phase 2 study of barzolvolimab for chronic spontaneous urticaria (CSU) at the EAACI Congress 2025. The study indicates that 41% of patients experienced a complete response seven months post-treatment, and 48% reported no impact on their quality of life. The safety profile was favorable, with no new safety signals identified, indicating the potential for barzolvolimab as a significant treatment option in CSU. Enrollment for Phase 3 trials is ongoing, highlighting the company's commitment to advancing this therapy.
Read more →CLDXCelldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Celldex (NASDAQ:CLDX) will present Phase 2 study data of barzolvolimab in chronic spontaneous urticaria at the EAACI Congress 2025 in Glasgow, Scotland. Abstracts will be available on June 12, with a company webcast scheduled for the same day. The presentations will cover the efficacy and tolerability data gathered over 76 weeks, as well as results from 52 weeks of treatment related to angioedema. The involvement of esteemed researchers highlights the significance of the findings.
Read more →CLDX▲ +9.3%on this newsshared move
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors HAMPTON, N.J.
Celldex Therapeutics has announced the election of Denice M. Torres to its Board of Directors. Torres brings a wealth of experience from her leadership roles in various pharmaceutical and consumer healthcare sectors. She is expected to contribute strategically to the company, particularly regarding their clinical programs and the potential of barzolvolimab. The company expresses optimism about her impact on advancing their innovative therapeutics.
Read more →CLDXCelldex Reports First Quarter 2025 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its financial results for Q1 2025, highlighting strong progress across its clinical pipeline. The ongoing Phase 2 studies for barzolvolimab demonstrate it may significantly improve the quality of life for patients with chronic spontaneous urticaria. However, the company reported a net loss of $53.8 million during this quarter. Celldex maintains a robust cash position to support its planned operations and research through 2027.
Read more →CLDXCelldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
Celldex presented histology data from its Phase 2 study of barzolvolimab for eosinophilic esophagitis (EoE) at the Digestive Disease Week 2025 conference. The data showed a significant presence of intraepithelial mast cells, suggesting their role in EoE pathology and potentially indicating barzolvolimab's efficacy. Enrollment for the study has concluded, with clinical results anticipated in the latter half of 2025. The findings contribute to growing evidence that mast cells are key contributors to EoE and could lead to better therapeutic options for patients.
Read more →CLDXCelldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has announced its participation in two upcoming investor conferences: the TD Cowen 45th Annual Health Care Conference on March 4th and the Leerink Partners Global Healthcare Conference on March 11th. Management will engage in fireside chats at both events, and live webcasts of these presentations will be available on their website. This participation highlights Celldex's commitment to transparency and investor engagement in their clinical-stage biotechnology efforts.
Read more →CLDX▼ -5.9%on this newsshared move
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Celldex Therapeutics has reported positive preclinical findings for CDX-622, a bispecific antibody targeting pathways related to inflammation and fibrosis. This evidence suggests CDX-622 effectively neutralizes SCF and TSLP, potentially improving treatment for conditions driven by these pathways. A Phase 1 clinical trial in healthy volunteers is currently ongoing to further evaluate its safety and effectiveness. Results were presented at the AAAAI Annual Meeting 2025, highlighting CDX-622's potential to enhance therapeutic benefits over existing single-target treatments.
Read more →CLDX▼ -5.9%on this newsshared move
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Celldex Therapeutics announced positive data from Phase 2 studies of barzolvolimab in patients with chronic urticaria, demonstrating significant improvements in disease control and quality of life. In the CSU trial, 82% of patients reported no impact from symptoms after 52 weeks, while 71% achieved complete response. The CIndU trial results indicated that 60% of patients reported a lack of symptoms affecting their quality of life after just 12 weeks. The findings, presented at the AAAAI Annual Meeting 2025, support barzolvolimab's potential to transform treatment for chronic urticaria patients.
Read more →CLDXCelldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its financial results for Q4 and the year ending December 31, 2024. Significant advances include ongoing Phase 3 trials for barzolvolimab in chronic spontaneous urticaria (CSU) and the initiation of a Phase 2 study in atopic dermatitis. Noteworthy efficacy data from barzolvolimab's Phase 2 studies highlight its potential as a leading treatment option. The company also initiated a Phase 1 study for a new bispecific antibody, CDX-622, targeting inflammatory diseases. However, Celldex faced a decline in revenue compared to previous periods and reported considerable cash burn during Q4.
Read more →CLDXCelldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Celldex Therapeutics has announced the initiation of a Phase 2 study of barzolvolimab for the treatment of moderate to severe atopic dermatitis (AD). The randomized, double-blind trial will evaluate the efficacy and safety of barzolvolimab compared to placebo and involve approximately 120 patients across 50 clinical trial centers in the U.S. The primary endpoint focuses on assessing the worst itch intensity in patients, highlighting the unmet need for new therapies in this population. The CMO of Celldex anticipates that the mast cell-targeting mechanism of barzolvolimab could significantly improve patient quality of life.
Read more →CLDX▲ +5.7%on this news
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Celldex Therapeutics has announced the initiation of a Phase 1a study for its bispecific antibody CDX-622, aimed at treating various inflammatory diseases. The first patient was dosed as part of this trial to evaluate safety and efficacy in healthy volunteers. CDX-622 works by neutralizing thymic stromal lymphopoietin and depleting mast cells, potentially offering a dual approach to inflammation-related conditions. The study will include assessments of biomarkers related to the therapy, with hopes of broad applications in respiratory and dermatological disorders.
Read more →CLDX▲ +8.7%on this newsshared move
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its third quarter 2024 financial results and provided updates on its clinical programs. The company highlighted successful completion of all primary and secondary endpoints in its Phase 2 studies for barzolvolimab in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Furthermore, the company plans to advance its bispecific antibody CDX-622, targeting inflammatory diseases, into clinical trials. Despite increasing R&D expenses and a decrease in cash position, Celldex remains optimistic about its pipeline and the potential impact of barzolvolimab for patients with severe conditions.
Read more →CLDXCelldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
Celldex Therapeutics announced positive results from a Phase 2 clinical trial of barzolvolimab for chronic inducible urticaria (CIndU). This study, which included patients unresponsive to standard antihistamine treatment, achieved all primary and secondary endpoints with high statistical significance. The drug was well-tolerated, with reports of mild adverse effects. Plans are in place to advance barzolvolimab into Phase 3 trials, targeting CIndU for potential commercialization in 2025.
Read more →CLDXCelldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
Celldex Therapeutics has announced that results from its Phase 2 clinical trial of barzolvolimab for treating chronic inducible urticaria will be presented at the ACAAI Annual Scientific Meeting. The findings will highlight the efficacy and safety of barzolvolimab in addressing two prevalent forms of this condition: cold urticaria and symptomatic dermographism. The presentation is set for October 26, 2024, and may attract significant interest from the medical community given the commonality and impact of these urticaria types.
Read more →CLDX▼ -12.1%on this news
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
Celldex Therapeutics has presented significant findings from a 52-week Phase 2 study of barzolvolimab in managing chronic spontaneous urticaria (CSU) at the EADV Congress 2024. The data highlights that 71% of patients treated with a 150 mg dose achieved a complete response over the treatment period. Improvements in disease symptoms were sustained or deepened throughout the study, indicating the treatment's robustness. Additionally, barzolvolimab was well tolerated with a favorable safety profile, suggesting its potential as a transformative therapy for patients with CSU.
Read more →CLDXCelldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
Celldex Therapeutics announced that its abstract detailing 52-week results of the Phase 2 trial for barzolvolimab in patients with chronic spontaneous urticaria has been accepted for a late-breaking oral presentation at the EADV Congress 2024 in Amsterdam. The data is expected to showcase the drug's efficacy and safety profile. An e-poster discussing improvements in quality of life due to barzolvolimab treatment will also be available during the congress. This development highlights Celldex's ongoing efforts in advancing its pipeline for serious inflammatory conditions.
Read more →CLDXCelldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics announced its second quarter 2024 financial results and updates regarding its clinical pipeline. The company reported positive topline results from its Phase 2 studies on barzolvolimab for chronic urticaria, supporting its advancement to Phase 3 trials. Additionally, they plan to initiate Phase 2 studies for atopic dermatitis by year-end 2024. Celldex is also set to introduce its bispecific therapy, CDX-622, targeting chronic inflammation into clinical trials.
Read more →CLDX▼ -5.8%on this news
Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria
Celldex Therapeutics reported positive topline results from a Phase 2 clinical trial of barzolvolimab for chronic inducible urticaria (CIndU). The study successfully met its primary endpoint, demonstrating a significant complete response rate among patients who were symptomatic despite antihistamine treatment. With favorable safety and tolerability profiles, the company plans to advance barzolvolimab into Phase 3 development. The trial results indicate that barzolvolimab could become a critical treatment option for patients suffering from CIndU.
Read more →CLDXCelldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Celldex Therapeutics has launched a global Phase 3 program to test barzolvolimab for adults with chronic spontaneous urticaria (CSU). The two trials, EMBARQ-CSU1 and EMBARQ-CSU2, will assess the efficacy and safety of the monoclonal antibody in over 1800 patients who have not responded adequately to standard treatments. Results from earlier studies indicate that barzolvolimab may effectively control CSU symptoms by targeting mast cell activity, representing a significant advancement in treatment options for affected patients.
Read more →CLDXCelldex Therapeutics to Present at Jefferies Healthcare Conference
Celldex Therapeutics announced its participation in the upcoming Jefferies Healthcare Conference, scheduled for June 6th at 10:00 am ET. The management will engage in a fireside chat, and a webcast of the presentation will be available on their website. This event highlights Celldex's focus on innovative therapeutics related to mast cell biology. A replay of the presentation will also be accessible for 90 days after the event.
Read more →CLDXCelldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024
Celldex Therapeutics has announced results from its Phase 2 study demonstrating significant improvements in angioedema for patients with chronic spontaneous urticaria (CSU). Presented at the EAACI Congress 2024, the data showed that barzolvolimab leads to profound and statistically significant reductions in angioedema symptoms within just two weeks. A majority of patients, including those previously resistant to omalizumab, exhibited substantial clinical benefits, reinforcing the drug's potential role as a transformative therapy for CSU. With these encouraging results, the company is set to launch Phase 3 trials in the coming months.
Read more →CLDXCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis
Celldex Therapeutics has announced the dosing of the first patient in a Phase 2 study evaluating barzolvolimab for prurigo nodularis, a chronic skin condition characterized by painful lesions and intense itching. The study follows positive results from a Phase 1b trial, where a single dose of barzolvolimab showed potential in breaking the itch-scratch cycle. The new study will assess the drug's efficacy and safety compared to a placebo over a treatment phase of 24 weeks among approximately 120 patients. As a response to the unmet medical need in treating this condition, barzolvolimab could offer significant relief and healing for patients. The trial will take place at multiple clinical centers globally, including in the United States.
Read more →CLDXCelldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its financial results for the first quarter of 2024 alongside a corporate update, highlighting promising Phase 2 clinical trial data for its drug barzolvolimab. The company successfully completed enrollment in its Phase 2 CIndU study and anticipates initiating Phase 3 studies for chronic spontaneous urticaria (CSU) soon. Celldex's impressive cash position of over $820 million supports its ongoing and future clinical development efforts, including a new focus on atopic dermatitis. However, the company saw a drop in revenue compared to the prior year, prompting scrutiny of its financial performance amidst rising research and development expenditures.
Read more →CLDXCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex Therapeutics has completed patient enrollment for its Phase 2 clinical study of barzolvolimab in treating chronic inducible urticaria (CIndU), specifically targeting cold urticaria and symptomatic dermographism. Barzolvolimab is a humanized monoclonal antibody that inhibits mast cell activation, a key factor in these conditions. The study aims to evaluate various dosing regimens in patients unresponsive to antihistamines, with topline results expected in the second half of 2024. This development could provide a new treatment option for patients, as no specific therapies for CIndU are currently available.
Read more →CLDXCelldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Celldex Therapeutics, Inc. announced its participation in the upcoming Leerink Partners Global Biopharma Conference scheduled for March 11, 2024. The event will include a fireside chat featuring management, providing a platform for the company to discuss its innovative therapies and engage with investors. A webcast of the presentation will be accessible on the company's website, with a replay available afterward. Celldex specializes in antibody-based therapeutics targeting severe inflammatory and autoimmune diseases, although it faces several uncertainties on its path to commercialization.
Read more →CLDXCelldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Celldex Therapeutics, Inc. has announced its participation in TD Cowen's 44th Annual Health Care Conference, where CEO Anthony S. Marucci will join an 'Inflammation & Immunology Corporate Panel Discussion.' The event is set for March 5, 2024, from 2:10 to 3:10 PM ET, and will be available for live streaming on the company's investor website. Celldex is recognized for its development of antibody-based therapeutics aimed at addressing severe inflammatory and autoimmune diseases.
Read more →CLDX▲ +7.9%on this newsshared move
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Celldex Therapeutics has announced the pricing of an upsized public offering of 8,520,000 shares at $47.00 each, aiming to raise approximately $400.4 million in gross proceeds. The offering, which includes an option for underwriters to purchase additional shares, aims to fund the development of its product candidates, including barzolvolimab, and support the expansion of its bispecific antibody platform. The offering is expected to close around March 5, 2024, subject to customary conditions.
Read more →CLDXCelldex Therapeutics Announces Proposed Public Offering of Common Stock HAMPTON, N.J.
Celldex Therapeutics has proposed a public offering of up to $250 million in common stock, with an option for underwriters to purchase an additional $37.5 million. The funds from this offering are intended to support ongoing clinical and preclinical development, including work on barzolvolimab and other pipeline products. The final terms of the offering hinge on market conditions and are not guaranteed, highlighting potential risks surrounding its completion.
Read more →CLDX▲ +27.8%on this newsshared move
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its fourth quarter and year-end 2023 financial results, highlighting significant advancements in its barzolvolimab development program. Positive data from Phase 2 studies, including successful trials in chronic spontaneous urticaria (CSU), have led to the planned initiation of Phase 3 studies in summer 2024. The company is also advancing its clinical programs for chronic inducible urticaria and prurigo nodularis, with further data expected in the second half of 2024. Additionally, Celldex's revenue has increased significantly due to services related to its research and development efforts.
Read more →CLDX▲ +27.8%on this newsshared move
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Celldex Therapeutics has announced positive results from its Phase 2 clinical trial of barzolvolimab for chronic spontaneous urticaria (CSU). The treatment met primary and secondary efficacy endpoints, showing meaningful reduction in disease activity within 12 weeks. Results indicated that patients previously treated with omalizumab experienced similar benefits, highlighting the drug's unique mechanism. The company anticipates further results and plans to initiate a Phase 3 trial in 2024.
Read more →CLDXCelldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Celldex Therapeutics, Inc. will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. Management will take part in a fireside chat, sharing insights on their ongoing projects. A webcast of the presentation will be made available on their website, providing an opportunity for wider audience engagement.
Read more →CLDXCelldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
Celldex Therapeutics announced the acceptance of an abstract detailing the 12-week results from its Phase 2 clinical trial of barzolvolimab for chronic spontaneous urticaria (CSU) at the upcoming AAAAI Annual Meeting 2024. The study, which included patients with moderate to severe CSU resistant to antihistamines, demonstrated positive outcomes regarding disease activity reduction. The findings will be presented as a late-breaking oral abstract on February 24, 2024, along with a subsequent live webcast on February 25, 2024.
Read more →CLDXCelldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
Celldex Therapeutics, Inc. announced its participation in the 6th Annual Evercore ISI HealthCONx Conference on November 28th. The event will feature a fireside chat with management, and a webcast will be available for viewing. This participation highlights the company's ongoing efforts to present its clinical advancements and engage with the investment community.
Read more →CLDX▼ -8.7%on this news
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
Celldex Therapeutics has announced the pricing for an underwritten public offering of 7,425,000 shares of its common stock at $27.00 per share, with gross proceeds expected to be around $200.5 million. The offering includes a 30-day option for underwriters to purchase additional shares. Proceeds from the offering will be utilized for clinical development of its product candidates, including barzolvolimab, and to fund ongoing projects within its pipeline. The closing of the offering is anticipated around November 10, 2023, subject to customary conditions.
Read more →CLDXCelldex Therapeutics Announces Proposed Public Offering of Common Stock
Celldex Therapeutics has announced a proposed public offering of its common stock, aiming to strengthen its financial position. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. The company plans to use the proceeds for various purposes, including the development of its product candidates and expanding its bispecific antibody platform. However, the outcome of the offering is contingent on market conditions and closing conditions, which introduces uncertainty.
Read more →CLDX▲ +13%on this newsshared move
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Celldex Therapeutics announced positive topline results from a Phase 2 study of barzolvolimab for treating chronic spontaneous urticaria (CSU), showing statistically significant reductions in urticaria disease activity. The drug was well-tolerated across multiple dosing regimens in patients refractory to antihistamines. Barzolvolimab's mechanism targets critical pathways in CSU, offering a new treatment avenue for patients. The company plans to advance the drug into further clinical development based on these promising results.
Read more →CLDX▲ +13%on this newsshared move
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
Celldex Therapeutics announced promising Phase 1b study results for barzolvolimab, a monoclonal antibody targeted at prurigo nodularis. The study demonstrated meaningful reductions in itching and skin lesions after a single intravenous dose of 3.0 mg/kg. Patients showed persistent improvements from as early as week 1, with planned Phase 2 studies set to start in early 2024. However, an adverse reaction was noted in a complicated patient, and the trial's sample size may limit broader applicability of the results.
Read more →CLDXCelldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its third quarter 2023 financial results and provided updates on ongoing clinical trials. The company completed enrollment of its Phase 2 chronic spontaneous urticaria (CSU) study ahead of schedule, with topline data expected by the end of the year. Additionally, the firm announced positive results from its Phase 1b study in prurigo nodularis and plans to initiate a Phase 2 study in early 2024. However, the company reported a net loss of $38.3 million for the quarter, which is a significant increase compared to the prior year.
Read more →CLDXCelldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
Celldex Therapeutics announced the acceptance of an abstract detailing the results of its Phase 1b study on barzolvolimab, aimed at treating prurigo nodularis. This study demonstrates both safety and clinically meaningful activity, and the results will be presented at the 12th World Congress on Itch in Miami from November 5-7, 2023. The presentation will be delivered by Dr. Martin Metz from Charité - Universitätsmedizin Berlin. This recognition highlights the company's commitment to addressing challenging diseases with inadequate treatments.
Read more →CLDXCelldex Therapeutics to Present at Cantor Global Healthcare Conference
Celldex Therapeutics, Inc. has announced its participation in a fireside chat at the Cantor Global Healthcare Conference scheduled for September 26th. The event will feature management discussing the company's clinical-stage biotechnology advancements. A webcast will be available for live viewing and for 90 days afterward on their website, ensuring broad accessibility for interested stakeholders. Celldex focuses on developing monoclonal and bispecific antibodies aimed at treating serious diseases.
Read more →CLDXCelldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics has reported its Q2 2023 financial results along with key pipeline updates. The company successfully completed enrollment for its Phase 2 trial of barzolvolimab for chronic spontaneous urticaria, with topline data expected by year-end. Additional studies for eosinophilic esophagitis and prurigo nodularis are set to begin, reflecting a robust advancement of their clinical programs. Recent presentations at EAACI 2023 showcased promising efficacy data for barzolvolimab in managing symptoms for chronic skin conditions.
Read more →CLDXCelldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Celldex Therapeutics has completed patient enrollment in its Phase 2 clinical study of barzolvolimab for chronic spontaneous urticaria, which is significant given the high unmet treatment needs in this condition. The study, which involved 208 patients, evaluates different dosing regimens of the monoclonal antibody, showing promise in a disease with limited existing therapies. The results from this trial are expected to be revealed before the end of the year, further indicating Celldex's commitment to addressing chronic spontaneous urticaria.
Read more →CLDXCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
Celldex Therapeutics, Inc. announced the dosing of the first patient in its Phase 2 study of barzolvolimab for eosinophilic esophagitis (EoE). The study aims to evaluate the efficacy and safety of barzolvolimab, a monoclonal antibody that inhibits mast cell activity. Approximately 60 patients will receive either the treatment or a placebo in a randomized, controlled trial. This important step comes amidst limited treatment options for EoE, as the study seeks to further validate the role of mast cells in this inflammatory disease.
Read more →CLDX▲ +6.6%on this news
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
Celldex Therapeutics presented positive data on barzolvolimab for chronic spontaneous urticaria (CSU) and cholinergic urticaria at the EAACI 2023 conference. The data revealed that 55% of patients achieved a complete response after 24 weeks, and the treatment showed significant efficacy in reducing angioedema symptoms. Barzolvolimab was well tolerated and achieved impressive results in quality of life improvements for cholinergic urticaria patients. The ongoing Phase 2 studies continue to support its potential as a promising treatment option.
Read more →CLDXCelldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
Celldex Therapeutics has announced that it will present data from its barzolvolimab program at the EAACI Annual Congress 2023 in Hamburg, Germany. The presentations will focus on the drug's clinical efficacy in treating chronic spontaneous urticaria and antihistamine refractory cholinergic urticaria. The sessions are set to take place on June 10, 2023, featuring distinguished professionals from Charité - Universitätsmedizin Berlin. This event represents an important opportunity for Celldex to showcase its advancements in treating inflammatory diseases.
Read more →CLDXCelldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
Celldex Therapeutics has announced the dosing of the first patient in a Phase 1 clinical trial for CDX-585, a bispecific antibody targeting PD-1 and ILT4 for the treatment of advanced solid tumors. This novel approach aims to overcome challenges associated with immunosuppressive signaling in T cells and myeloid cells. The trial will assess the safety and efficacy of CDX-585 in patients whose tumors have progressed post-standard therapy. Notably, preclinical studies have demonstrated its potent antagonistic effects, showing promise for its future application in oncologic treatments.
Read more →CLDXCelldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
Celldex Therapeutics recently presented promising preclinical data for its bispecific antibody CDX-622, which targets both TSLP and SCF, at the IMMUNOLOGY2023™ conference. The data indicates CDX-622 effectively neutralizes TSLP and inhibits SCF/KIT interactions critical for mast cell function. This combination approach may enhance efficacy in treating various inflammatory, fibrotic, and allergic disorders. The findings support the advancement of CDX-622 into further development and regulatory activities.
Read more →CLDXCelldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Celldex Therapeutics reported its first quarter 2023 financial results, highlighting positive developments in its barzolvolimab studies. The company expects to complete enrollment in its Phase 2 chronic spontaneous urticaria (CSU) study by the end of Q3 2023, with topline data due later this year or early next year. Additionally, barzolvolimab has demonstrated a favorable safety profile and significant efficacy in patients resistant to antihistamine treatment. The company plans to initiate a Phase 2 study in eosinophilic esophagitis in June 2023 and is also preparing for upcoming presentations at the EAACI Hybrid Congress.
Read more →CLDXCelldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Celldex Therapeutics, Inc. (NASDAQ:CLDX) will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30th. The company specializes in developing monoclonal and bispecific antibodies targeting inflammatory diseases and various forms of cancer. This event presents an opportunity for Celldex to discuss their pipeline and advancements with potential investors. A webcast of the presentation will be available, and a replay can be accessed for up to 90 days afterward.
Read more →CLDXCelldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
Celldex Therapeutics, Inc. announced its fourth-quarter and year-end financial results for 2022, highlighting advancements in its barzolvolimab program. The company reported positive data from Phase 1b studies and expects to complete enrollment for the Phase 2 study in chronic spontaneous urticaria by Q3 2023. Dr. Rita Jain was appointed to the board, adding expertise in drug development. Upcoming milestones include topline data reporting from the CSU study anticipated by late 2023 or early 2024.
Read more →CLDX▲ +7.3%on this newsshared move
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
Celldex Therapeutics presented promising Phase 1b study results for barzolvolimab in treating chronic spontaneous urticaria (CSU). The clinical trial reported that 56% of patients achieved a complete response after 12 weeks, with a favorable safety profile observed. Notably, the drug showed effectiveness even in patients previously treated with omalizumab. Continuing trials will further assess the treatment's potential as a front-line therapy for CSU and other mast cell-related conditions.
Read more →CLDXCelldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors HAMPTON, N.J., February 16 , 2023 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to t
Celldex Therapeutics has announced the appointment of Dr. Rita Jain, M.D. to its Board of Directors. This addition is seen as a strategic move to enhance the Board's capabilities in drug development, as Dr. Jain brings extensive experience from various leadership roles in the biopharmaceutical sector. Both CEO Anthony Marucci and Dr. Jain have expressed optimism about advancing Celldex's programs, particularly in relation to the potential of barzolvolimab in treating challenging diseases in allergy, inflammation, and immunology. Dr. Jain's previous roles include Chief Medical Officer at several biopharma companies, indicating her strong background in the industry.
Read more →CLDXCelldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
Celldex Therapeutics has appointed Dr. Rita Jain to its Board of Directors, enhancing its leadership with her extensive experience in drug development. Dr. Jain has previously held key roles at multiple biotech companies, focusing on various therapeutic areas. Her expertise is expected to help advance Celldex's therapeutic programs, particularly in relation to barzolvolimab, which shows promise in treating difficult diseases across several medical conditions.
Read more →CLDXCelldex Therapeutics to Present at SVB Securities Global Biopharma Conference
Celldex Therapeutics, Inc. announced its participation in the SVB Securities Global Biopharma Conference, scheduled for February 15, 2023. The company will host a fireside chat at 9:20 AM ET, which will be accessible via a webcast on their website. The event highlights Celldex's commitment to transparency and investor relations as it advances its pipeline of innovative therapies targeting serious diseases. A replay of the presentation will be available for 90 days post-event.
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
Celldex Therapeutics, Inc. (NASDAQ: CLDX) has announced that it will present data from its Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria at the American Academy of Allergy, Asthma & Immunology Annual Meeting 2023. The meeting, scheduled for February 24-27 in San Antonio, Texas, will feature a detailed presentation on the safety and clinical activity of multiple doses of barzolvolimab. The webcast of the presentation is set for February 26th, further demonstrating the company's ongoing commitment to developing innovative treatments for inflammatory diseases.
Read more →CLDXCelldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
- 100% complete response rate in cold urticaria after single dose of barzolvolimab at 1.5 mg/kg, including in omalizumab refractory patients - - Long term follow up of patients with chronic inducible urticaria treated at 3.0 mg/kg confirm that barzolvolimab-induced responses and
Read more →CLDXCelldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA LEN Global Urticaria Forum (GUF) 2022
- Includes oral presentation for 1.5 mg/kg cold urticaria cohort - - Company to host webcast conference call on Tuesday, December 6 at 8:00 am ET - HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentati
Read more →CLDX▲ +16%on this news
Celldex to Participate in Upcoming November Investor Conferences
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November: Guggenheim 4th Annual Immunology and Neurology Conference on Monday, No
Read more →CLDX▼ -5.7%on this newsshared move
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Multiple clinical-stage programs on track for data updates in upcoming months - HAMPTON, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2022 and provided a corporate up
Read more →CLDXCelldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Positive interim data from barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria presented at EAACI 2022 - - First patients dosed in Phase 2 chronic urticaria studies - HAMPTON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today rep
Read more →CLDXCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU) - col
Read more →CLDXCelldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
-Rapid, profound and durable responses across multiple dosing groups with favorable safety profile- -Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg dose group (reflects one dose; ongoing)-
Read more →CLDXCelldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized mono
Read more →CLDXCelldex Announces Two New Appointments to its Board of Directors
HAMPTON, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Cheryl L. Cohen and Dr. Garry Neil to the company’s Board of Directors. “We are thrilled to welcome Cheryl and Garry to our Board of Directors during a
Read more →CLDXCelldex to Present at the 2022 Jefferies Global Healthcare Conference
HAMPTON, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference in New York City on Wednesday, June 8, 2022 at 8:30 a.m. ET. A
Read more →CLDXCelldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as
Read more →CLDX▼ -5.6%on this news
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
HAMPTON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “This quarter, we continued to focus on advancing our clinical programs and are o
Read more →CLDXCelldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
CSU Phase 1b multi-dose data expected in July CDX-0159 subcutaneous formulation study results fully support transition to SubQ dosing; Phase 2 studies in CSU and CIndU to initiate Q2 2022 Expanded development of CDX-0159 into Eosinophilic Esophagitis (EoE) Well capitalized wit
Read more →CLDXCelldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
HAMPTON, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced it will host a conference call and webcast on Monday, February 28, 2022 at 4:30 p.m. ET to discuss its fourth quarter and full year 2021 financial results and corporate highl
Read more →CLDXCelldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
HAMPTON, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:00 p.m. ET
Read more →CLDXCelldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specificall
Read more →CLDX▼ -5.5%on this news
Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021
HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody pla
Read more →CLDXCelldex to Participate in Upcoming Investor Conferences
HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November: Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Confere
Read more →CLDXCelldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update
HAMPTON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “During the third quarter we reported compelling data from our ongoing Phase
Read more →CLDXCelldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021
- Rapid and sustained improvement in urticaria control after single dose of CDX-0159 - - Greatly improved patient quality of life and reduced disease impact - - Data further support 95% complete response rate to provocation testing - HAMPTON, N.J., Sept. 29, 2021 (GLOBE NEWSWI
Read more →CLDXCelldex to Present at the 2021 Cantor Virtual Global Healthcare Conference
HAMPTON, N.J., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29, 2021 at 1:20 p.m. ET. A webca
Read more →CLDXCelldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urtic
Read more →CLDXCelldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that
Read more →CLDX▲ +6.4%on this news
Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021 - HAMPTON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therape
Read more →CLDXCelldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock
HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 5,952,381 shares of its common stock at a public offering price of $42.00 per share. In connec
Read more →CLDXCelldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021
- 95% complete response rate after single dose of CDX-0159 - - Rapid, profound and durable responses offer patients opportunity for quick, lasting, meaningful relief - - Median duration of response 77+ days in Cold Urticaria and 57+ days in Symptomatic Dermographism - - Serum
Read more →CLDXCelldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies. These data were presented
Read more →CLDXCelldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021
HAMPTON, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism
Read more →CLDXCelldex to Present at the Jefferies 2021 Virtual Healthcare Conference
HAMPTON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:30 p.m. ET. A webcast of the pr
Read more →CLDXCelldex Reports First Quarter 2021 Financial Results and Provides Corporate Update
HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. “We are very encouraged by the recently reported positive interim results from ou
Read more →CLDXCelldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021
HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company’s growing bispecific platform at the American Association of Cancer Research (AACR) Annual Meeting 2021 being held April
Read more →CLDXCelldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results
HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. “Celldex made significant progress across our pipeline in 2020 and today continued
Read more →CLDXCelldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria
--CDX-0159 generally well tolerated to date-- --Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported interim data from the Company’s ongoing, open label clinical trial of CD
Read more →CLDXCelldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference
HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference. The presentation for the virtual conference was prerecorded and will b
Read more →CLDXCelldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference
HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 2:20 p.m. ET. A webcast o
Read more →CLDXCelldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)
--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation-- --Potential to expand future CDX-0159 development beyond chronic urticarias to chronic prurit
Read more →CLDXCelldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel HAMPTON, N.J.
Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel N.J., January 4, 2021 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the promotion of Freddy A. Jimenez, Esq. to Senior Vice President and General Counsel, effective January 1, 2021. Over
Read more →CLDXCelldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria
HAMPTON, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the first patient has been dosed in its open label clinical trial in cold contact urticaria and symptomatic dermographism, the two most common forms of chronic inducible
Read more →CLDXCelldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference
HAMPTON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 pm ET. A webcast of the presentati
Read more →CLDXCelldex Presents Data from Oncology Portfolio at SITC 2020
-- Agonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from multiple
Read more →CLDXCelldex Provides Corporate Update and Reports Third Quarter 2020 Results
HAMPTON, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2020. “In the third quarter, building on the compelling CDX-0159 data presented at EAACI, we initi
Read more →CLDXCelldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria
HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU
Read more →CLDXCelldex Therapeutics to Present at Upcoming Healthcare Conferences
HAMPTON, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company will participate in Fireside Chats at the Cantor Virtual Global Healthcare Conference and the HC Wainwright & CO 22nd Annual Global Investment Virtual Confe
Read more →CLDXCelldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
HAMPTON, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-527 in patients with advanced or metastatic solid tumors that have progressed during or after standard of c
Read more →CLDXCelldex Provides Corporate Update and Reports Second Quarter 2020 Results
HAMPTON, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2020. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipelin
Read more →CLDXCelldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call
HAMPTON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the s
Read more →CLDXCelldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the unde
Read more →CLDXCelldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the pricing of its previously announced underwritten public offering. Celldex is offering 13,377,926 shares of its common stock, par value $0.0
Read more →CLDXCelldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile
--Data strongly support expanding development into mast cell driven diseases-- --Data presented in a late-breaking session at EAACI Annual Congress 2020-- HAMPTON, N.J., June 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced results from the
Read more →CLDXCelldex Provides Corporate Update and Reports First Quarter 2020 Results
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2020. “Despite the ongoing challenges associated with the COVID-19 pandemic, Celldex continued to make
Read more →CLDXCelldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020
HAMPTON, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that results from the Phase 1 study of CDX-0159 have been accepted as a late-breaking poster presentation with voice over at the European Academy of Allergy and Clinical Immun
Read more →CLDXCelldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
HAMPTON, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2019. “We are pleased that Celldex entered 2020 with significant momentum, following exc
Read more →CLDXCelldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program
HAMPTON, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company will receive a $1.7 million payment related to an existing 2013 agreement with Rockefeller University under which Celldex performed manufacturing and develo
Read more →CLDXCelldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159
HAMPTON, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that a Phase 1a study of CDX-0159 has initiated in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifically binds the KIT receptor and potently inhib
Read more →CLDXCelldex Provides Corporate Update and Reports Third Quarter 2019 Results
HAMPTON, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2019. “Celldex achieved a significant milestone last week, reporting data at SITC that CDX-1140 ha
Read more →CLDXCelldex Presents Promising Data from CDX-0159 and CDX-527 Programs
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019- -CDX-527 on track for IND filing in 1H 2020- HAMPTON, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s preclinical pipeline this weekend. A review of the
Read more →CLDXCelldex Therapeutics Announces Upcoming Data Presentations
HAMPTON, N.J., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. Society for Immunotherapy of Cancer (SIT
Read more →CLDXCelldex Therapeutics to Present at the Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Tibor Keler, PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present
Read more →CLDXCelldex Provides Corporate Update and Reports Second Quarter 2019 Results
HAMPTON, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2019. The Company will host a conference call at 4:30 p.m. ET today to provide an update on its pipelin
Read more →CLDXCelldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call
HAMPTON, N.J., July 31, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2019 financial results on Wednesday, August 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the
Read more →CLDXCelldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer HAMPTON, N.J.
Celldex Therapeutics Appoints Diane C. Young, M.D. as Senior Vice President, Chief Medical Officer HAMPTON, N.J., June 24, 2019 Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of Diane C. Young, M.D., as Senior Vice President, Chief Medical Officer, effe
Read more →CLDXCelldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
--Evaluation of biomarkers for patient selection to be incorporated into expanded development program-- HAMPTON, N.J., June 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented results from the CDX-3379 clinical program at the 2019 American Socie
Read more →CLDXCelldex Provides Corporate Update and Reports First Quarter 2019 Results
HAMPTON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex presented positive data across multiple programs at AACR in April, including from our pr
Read more →CLDXCelldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
--CDX-1140 has achieved good systemic exposure without reaching a maximum tolerated dose to date-- --Addition of dendritic cell growth factor CDX-301 enhances cytokine response without additive toxicity at dose levels tested to date-- --Tumor specific expansion cohorts planned-
Read more →CLDXCelldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019
HAMPTON, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented promising data from the Company’s growing bispecific and TAM (Tyro3, Axl, MerTK) receptor programs during poster sessions today at the American Association for Cancer Research (AA
Read more →CLDXCelldex Provides Corporate Update and Reports Full Year 2018 Results
HAMPTON, N.J., March 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2018. The Company will host a conference call at 4:30 p.m. ET today to provide an update
Read more →CLDXCelldex to Report Full Year 2018 Business/Financial Results and Host Corporate Update Call
HAMPTON, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2018 financial results on Thursday, March 7, 2019 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m
Read more →CLDXCelldex Therapeutics Announces Reverse Stock Split
HAMPTON, N.J., Feb. 08, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) (“Celldex” or the “Company”) today announced that its Board of Directors has approved a one-for-fifteen reverse stock split of its common stock that became effective today upon the filing wi
Read more →CLDXCelldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Antibody technology provides an exciting new approach to enhance innate immune function in cancer HAMPTON, N.J., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data from the Company’s MerTK antibody program in a poster session today at the S
Read more →CLDXCelldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
--Well tolerated; dose dependent biological effects consistent with CD40-mediated immune cell activity-- --Program development expanded based on results observed to date-- HAMPTON, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interi
Read more →CLDXCelldex Provides Corporate Update and Reports Third Quarter 2018 Results
HAMPTON, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2018. “We made considerable progress in the third quarter, particularly in the development program
Read more →CLDXCelldex Provides Corporate Update and Reports Second Quarter 2018 Results
HAMPTON, N.J., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2018. The Company will host a conference call at 4:30 p.m. ET today to provide an in-depth update on it
Read more →CLDXCelldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call
HAMPTON, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2018 financial results on Wednesday, August 8, 2018 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the
Read more →CLDXCelldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo at 2018 ASCO Annual Meeting
-- CDX-3379 also featured in a “clinical trials in progress” presentation -- HAMPTON, N.J., June 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented two programs at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Read more →CLDXCelldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
HAMPTON, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 7, 2018
Read more →CLDXCelldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
HAMPTON, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The schedule for the presen
Read more →CLDXCelldex Provides Corporate Update and Reports First Quarter 2018 Results
HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2018. “Celldex has made considerable progress on an important strategic prioritization of our pipeline,
Read more →CLDXCelldex’s METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint
HAMPTON, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported that the Company’s randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers th
Read more →CLDXCelldex Provides Corporate Update and Reports Full Year 2017 Results
HAMPTON, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2017. The Company will host a conference call at 4:30 p.m. ET today to provide an in-dept
Read more →CLDXCelldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference
HAMPTON, N.J., March 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events in March. 2017 Year-End Results and Conference Call/Webcast Celldex will release fourth quarter and year-end 2017 financial results on Wednesday,
Read more →CLDXCelldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
HAMPTON, N.J., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-1140 in patients with advanced solid tumors. CDX-1140 is a fully human antibody targeted to CD40, a key act
Read more →CLDXCelldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
HAMPTON, N.J., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label Phase 2 study of CDX-3379 in combination with cetuximab in patients with cetuximab-refractory, advanced head and neck squamous ce
Read more →CLDXCelldex Reports Third Quarter 2017 Results
HAMPTON, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2017. "In late August, we completed enrollment in our Phase 2 METRIC study of glembatumumab vedoti
Read more →CLDXCelldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs HAMPTON, N.J.
Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs HAMPTON, N.J., October 3, 2017 Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Margo Heath-Chiozzi, M.D., has joined the Company as Senior Vice President, Regulato
Read more →CLDXCelldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
HAMPTON, N.J., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on September
Read more →CLDXCelldex Announces Departure of Chief Medical Officer HAMPTON, N.J.
Celldex Announces Departure of Chief Medical Officer HAMPTON, N.J., September 12, 2017 Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today the resignation of Thomas Davis, M.D., Executive Vice President and Chief Medical Officer of Celldex, effective September 29, 2017. C
Read more →CLDXCelldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer
HAMPTON, N.J., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that patient enrollment has been completed in the Company's Phase 2b METRIC study of glembatumumab vedotin in patients with metastatic triple negative breast cancers that ove
Read more →CLDXCelldex Reports Second Quarter 2017 Results
HAMPTON, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2017. "In the second quarter, we continued to see strong physician enthusiasm for our Phase 2 METRIC s
Read more →CLDXCelldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call
HAMPTON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2017 financial results on Tuesday, August 8, 2017 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the s
Read more →CLDXCelldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team HAMPTON, N.J.
Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team HAMPTON, N.J., June 16, 2017 Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced additions to the Board of Directors and senior management team: Keith L. Brownlie was elected to
Read more →CLDXCelldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference
HAMPTON, N.J., June 06, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Co-founder, Executive Vice President and Chief Scientific Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will p
Read more →CLDXCelldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo at 2017 ASCO Annual Meeting
HAMPTON, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today data from the Phase 1 portion of a Phase 1/2 dose escalation and cohort expansion study examining the combination of varlilumab, Celldex's CD27 targeting investigational immu
Read more →CLDXCelldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma
HAMPTON, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented positive, mature results from the Company's Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK
Read more →CLDXCelldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting
HAMPTON, N.J., May 17, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that clinical results from the single-agent cohort of the Phase 2 study of glembatumumab vedotin in patients with metastatic melanoma and the Phase 1 dose-escalation study of
Read more →CLDXCelldex Reports First Quarter 2017 Results
HAMPTON, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2017. “In the first quarter of 2017, Celldex made considerable progress across our pipeline,” said Anth
Read more →CLDXCelldex Provides Corporate Update and Reports Full Year 2016 Results
HAMPTON, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year-ended December 31, 2016. The Company will host a conference call at 4:30 p.m. ET today to provide an in-dept
Read more →CLDXCelldex Therapeutics Announces Appointment to Board of Directors HAMPTON, N.J.
Celldex Therapeutics Announces Appointment to Board of Directors HAMPTON, N.J., March 1, 2017 Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the appointment of James J. Marino, J.D., to the Company s Board of Directors. Mr. Marino was with the global law firm of Decher
Read more →CLDXCelldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call
HAMPTON, N.J., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events for February and March. Upcoming Investor Conferences Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., E
Read more →CLDXCelldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting
HAMPTON, N.J., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist and anti-lymphoma activity. Found on antigen presenting cells,
Read more →CLDXTheresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team HAMPTON, N.J.
Theresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team HAMPTON, N.J., December 5, 2016 Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company has hired Theresa LaVallee, Ph.D., to the newly created position of Senior Vice President, Regula
Read more →CLDXCelldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals HAMPTON, N.J.
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals HAMPTON, N.J. November 29, 2016 Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today it has completed its previously announced acquisition of Kolltan Pharmaceuticals, Inc., a privately held company focuse
Read more →CLDXCelldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
HAMPTON, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented data on new product candidate CDX-1140, a fully human antibody targeted to CD40 that has demonstrated potent agonist activity. Found on antigen presenting cells, such as dendritic
Read more →CLDXCelldex Reports Third Quarter 2016 Results
HAMPTON, N.J., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2016. “Celldex continues to demonstrate our commitment to combining therapeutic approaches to driv
Read more →CLDXCelldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals Conference call to be held at 4:30 p.m. Eastern Time today HAMPTON, N.J., and
Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals Conference call to be held at 4:30 p.m. Eastern Time today HAMPTON, N.J., and NEW HAVEN, Conn., November 1, 2016 Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that
Read more →CLDXCelldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
HAMPTON, N.J., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fi
Read more →CLDXCelldex Appoints Elizabeth Crowley as Chief Product Development Officer HAMPTON, N.J.
Celldex Appoints Elizabeth Crowley as Chief Product Development Officer HAMPTON, N.J., August 11, 2016 Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company has promoted Elizabeth Crowley to the newly created position of Senior Vice President, Chief Product
Read more →CLDXCelldex Reports Second Quarter 2016 Results
HAMPTON, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2016. “Celldex continues to build one of the most robust pipelines in immuno-oncology, most recently a
Read more →CLDXCelldex to Report Second Quarter 2016 Financial Results and Host Corporate 2016 Objectives Update Call
HAMPTON, N.J., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2016 financial results on Monday, August 8, 2016 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the sa
Read more →CLDXCelldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma
HAMPTON, N.J., July 11, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its Phase 1/2 study of CDX-014 in advanced renal cell carcinoma (RCC). CDX-014 is a novel antibody-drug conjugate that targets the transmembrane
Read more →CLDXCelldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference
HAMPTON, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, will participate in a fireside chat at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Read more →CLDXCelldex Therapeutics’ CDX‑1401, CDX‑301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma
HAMPTON, N.J., June 04, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today results from a Phase 2 clinical study evaluating CDX‑1401 and CDX‑301 in patients with malignant melanoma, which was conducted by the Cancer Immunotherapy Trials Network (CIT
Read more →CLDXCelldex Reports First Quarter 2016 Results
HAMPTON, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2016. “While the recent setback of the RINTEGA program was certainly a disappointment, the Company is f
Read more →CLDXCelldex Therapeutics Initiates Phase 1/2 Study of Glembatumumab Vedotin in Squamous Cell Lung Cancer
HAMPTON, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 1/2 safety and tolerability study of glembatumumab vedotin in patients with unresectable stage IIIB or IV, gpNMB-expressing, advanc
Read more →CLDXCelldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin and the Preclinical CD40 Program at the AACR Annual Meeting 2016
HAMPTON, N.J., April 20, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. The Company previously reported on four poster presentations
Read more →CLDXCelldex Therapeutics Presents Favorable Safety Profile and Immune Response Data from Phase 1/2 Study of Varlilumab and Nivolumab at the AACR Annual Meeting 2016
-- All varlilumab dose levels showed acceptable tolerability/safety in combination regimen; Phase 2 portion of study now open to enrollment -- -- Celldex and collaborating investigators presenting seven posters on pipeline programs at AACR 2016 -- HAMPTON, N.J., April 18, 2016
Read more →CLDXCelldex Therapeutics to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2016
HAMPTON, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR)
Read more →CLDXCelldex Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
HAMPTON, N.J., March 03, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference on Tue
Read more →CLDXCelldex Reports Fourth Quarter and Year-End 2015 Results
HAMPTON, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2015. “2015 was a year of considerable progress for Celldex and our growing pipeline,” sa
Read more →CLDXCelldex Presents Preliminary Cohort Data from Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Harvest at the 2016 BMT Tandem Meeting
HAMPTON, N.J., Feb. 20, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented new clinical data on CDX-301 (recombinant human Flt3 ligand), a potent hematopoietic cytokine that uniquely expands dendritic cells and hematopoietic stem cells. An open labe
Read more →CLDXCelldex to Report Fourth Quarter and Year-End 2015 Business/Financial Results and Host 2016 Corporate Strategy Conference Call
HAMPTON, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2015 financial results on Thursday, February 25, 2016 before the U.S. financial markets open. Celldex executives will host a conference call at 8:00
Read more →CLDXCelldex Therapeutics to Present at the Leerink Partners 5th Annual Global Healthcare Conference
HAMPTON, N.J., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fir
Read more →CLDXCelldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Atezolizumab in Renal Cell Carcinoma
HAMPTON, N.J., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and Roche's atezolizumab (MPDL3280A) in patien
Read more →CLDXCelldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
-- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- -- Clinical experience with varlilumab is consistent with immune co-stimulation and regulatory T cell depletion mechanisms, a potential unique benefit for varlilumab -- -- Multipl
Read more →CLDXCelldex Reports Third Quarter 2015 Results
HAMPTON, N.J., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2015. "Celldex continues to advance one of the most robust, well-staged pipelines in immuno-oncolog
Read more →CLDXCelldex Therapeutics to Present at the Leerink Partners Immuno-Oncology Roundtable
HAMPTON, N.J., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fi
Read more →CLDXCelldex Reports Second Quarter 2015 Results
HAMPTON, N.J., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2015. "Celldex is acutely aware of the significant unmet need for patients with glioblastoma, and we c
Read more →CLDXCelldex to Report Second Quarter 2015 Financial Results and Host Corporate 2015 Objectives Update Call
HAMPTON, N.J., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2015 financial results on Monday, August 10, 2015 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the sa
Read more →CLDXCelldex Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference
HAMPTON, N.J., July 2, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, will present a corporate overview at the Cantor Fitzgerald Inaugural Healthcare Conference on J
Read more →CLDXCelldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
HAMPTON, N.J., July 1, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced the promotion of Richard Wright, Ph.D. to Senior Vice President and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commerc
Read more →CLDXCelldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
HAMPTON, N.J., May 28, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib (SUTENT ) in patients with metas
Read more →CLDXCelldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference
HAMPTON, N.J., May 27, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2015 Global Healthcare Conference on June 3, 2015 a
Read more →CLDXCelldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting
HAMPTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that several clinical programs, including the Phase 2 ReACT study of RINTEGA (rindopepimut) in patients with recurrent glioblastoma (GBM), will be presented at the 2015 Americ
Read more →CLDXCelldex Reports First Quarter 2015 Results
HAMPTON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2015. "2015 began with a significant accomplishment for RINTEGA -the granting of Breakthrough Therapy
Read more →CLDXCelldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
HAMPTON, N.J., April 20, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today preclinical results that further support varlilumab's expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled "Synergis
Read more →CLDXCelldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
HAMPTON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study
Read more →CLDXCelldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
HAMPTON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and ipilimumab (Yervoy ; Bristol-Myers Squibb) in patie
Read more →CLDXCelldex Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate the Combination of Varlilumab and MPDL3280A
HAMPTON, N.J., March 17, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex's CD27 targeting inve
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health Care Conference
HAMPTON, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company is scheduled to present a corporate overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, at 8:40 am ET at the Boston M
Read more →CLDXCelldex Announces Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., Feb. 27, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,087,500 shares of common sto
Read more →CLDXCelldex Therapeutics Prices Public Offering of Common Stock HAMPTON, NJ (
Celldex Therapeutics Prices Public Offering of Common Stock HAMPTON, NJ (February 25, 2015): Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock, offered at a price to the public of $24.
Read more →CLDXCELLDEX REPORTS FOURTH QUARTER AND YEAR-END 2014 RESULTS Conference Call Scheduled for 8:00 a.m. ET Today HAMPTON, NJ (
CELLDEX REPORTS FOURTH QUARTER AND YEAR-END 2014 RESULTS Conference Call Scheduled for 8:00 a.m. ET Today HAMPTON, NJ (February 24, 2015): Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported business and financial highlights for the fourth quarter and year ended December 3
Read more →CLDXCelldex's Rindopepimut (Rintega(R)) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-positive Glioblastoma
HAMPTON, N.J., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the U.S. Food and Drug Administration (FDA) has granted rindopepimut (Rintega ) Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positi
Read more →CLDXCelldex to Report Fourth Quarter and Fiscal 2014 Business/Financial Results and Host 2015 Corporate Strategy Conference Call
--Conference Call Scheduled for Tuesday, February 24 at 8:00 a.m. Eastern Time-- HAMPTON, N.J., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2014 financial results on Tuesday, February 24, 2015 before the U.S
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation at the 2015 Leerink Global Healthcare Conference
HAMPTON, N.J., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Executive Vice President and Chief Medical Officer, are scheduled to present a corporate over
Read more →CLDXCelldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) in Advanced Refractory Solid Tumors
HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex'
Read more →CLDXCelldex Therapeutics Announces Appointment to Board of Directors
HAMPTON, N.J., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the appointment of Richard A. van den Broek to the Company's Board of Directors. Mr. van den Broek currently serves as a Managing Partner of HSMR Advisors, LLC, an investment
Read more →CLDXCelldex Announces Completion of Enrollment in Phase 3 Study of Rindopepimut in Frontline Glioblastoma
HAMPTON, N.J., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that patient enrollment has been completed in the Company's Phase 3 ACT IV study of rindopepimut in EGFRvIII positive glioblastoma, an aggressive form of brain cancer. "We a
Read more →CLDXCelldex Therapeutics Initiates a Phase 2 Study of Glembatumumab Vedotin in Patients with Advanced Melanoma
HAMPTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has initiated an open-label Phase 2 study of glembatumumab vedotin (CDX-011) in patients with unresectable Stage III or IV melanoma. Glembatumumab vedotin is a fully-h
Read more →CLDXCelldex Presents Varlilumab Proof of Concept Data at SITC Annual Meeting 2014
HAMPTON, N.J., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today presented a comprehensive review of the Company's Phase 1 single-agent study of varlilumab, focusing on biomarker analyses and confirming significant immunological effects consistent wi
Read more →CLDXCelldex Reports Third Quarter 2014 Results
HAMPTON, N.J., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the third quarter ended September 30, 2014. "In the third quarter, we significantly advanced a number of key programs," said Anthony Maru
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentations of Rindopepimut Data at 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)
-Interim data from Phase 2 ReACT study of rindopepimut in recurrent GBM to be presented- -Additional presentations on rindopepimut compassionate use experience and EGFRvIII vaccine technology- HAMPTON, N.J., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CL
Read more →CLDXCelldex Announces Publication of Glembatumumab Vedotin Phase 1/2 Studies in the Journal of Clinical Oncology
HAMPTON, N.J., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology (JCO). The pap
Read more →CLDXCelldex Therapeutics Initiates Pilot Study of CDX-301 in Allogeneic Hematopoietic Stem Cell Transplantation
HAMPTON, N.J., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies underg
Read more →CLDXCelldex Announces Upcoming Presentation at the Morgan Stanley Healthcare Conference
HAMPTON, N.J., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Morgan Stanley Healthcare Conference on September 8, 2014 at 1:25 p.m. E
Read more →CLDXCelldex Reports Second Quarter 2014 Results
HAMPTON, N.J., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the second quarter ended June 30, 2014. "Celldex has made tremendous progress advancing our pipeline this year-most notably, we will comp
Read more →CLDXCelldex Therapeutics Announces Senior Leadership Promotions
HAMPTON, N.J., July 30, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced three promotions in the Company's clinical and research departments: Tibor Keler, PhD promoted to Executive Vice President and Chief Scientific Officer; Thomas Davis, MD pr
Read more →CLDXCelldex to Report Second Quarter 2014 Financial Results and Host Corporate 2014 Objectives Update Call
HAMPTON, N.J., July 18, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release second quarter 2014 financial results on Wednesday, August 6, 2014 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. ET on the
Read more →CLDXCelldex Therapeutics' Varlilumab Continues to Demonstrate Very Favorable Profile
--Very well tolerated with notable immunologic and anti-tumor activity in Phase 1 Study; Will enter multiple combination studies in 2H 2014-- --Data presented at ASCO Annual Meeting 2014-- HAMPTON, N.J., June 2, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX)
Read more →CLDXCelldex Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference
HAMPTON, N.J., May 28, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference on June 4, 2014 at 10:30 a.m.
Read more →CLDXCelldex Therapeutics Announces Varlilumab (CDX-1127) Phase 1 Clinical Data to be Presented at ASCO Annual Meeting 2014
HAMPTON, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from its Phase 1 study of varlilumab, a fully human monoclonal antibody targeting CD27, will be presented at the American Society of Clinical Oncology (ASCO) Annual
Read more →CLDXBristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab (NEW YORK and HAMPTON, NJ
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab (NEW YORK and HAMPTON, NJ May 14, 2014) - Bristol-Myers Squibb Company (NYSE: BMY) and Celldex Therapeutics
Read more →CLDXCelldex to Present at Two Upcoming Investor Conferences
HAMPTON, N.J., May 2, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 39th Annual Healthcare Conference on Wednesday, May 7, 2014
Read more →CLDXCelldex Reports First Quarter 2014 Results
HAMPTON, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the first quarter ended March 31, 2014. "Celldex continues to advance one of the most robust, well-staged pipelines in immuno-oncology," s
Read more →CLDXCelldex's Phase 1 Study of CDX-1401 Published in Science Translational Medicine
--First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity-- HAMPTON, N.J., April 16, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that final data from
Read more →CLDXCelldex Therapeutics Establishes Preclinical Proof of Concept for New Antibody Drug Conjugate CDX-014; Data presented at AACR 2014
HAMPTON, N.J., April 7, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CD
Read more →CLDXCelldex Therapeutics to Present Antibody-Drug Conjugate CDX-014 Preclinical Proof of Concept Data at AACR 2014
HAMPTON, N.J., April 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate (ADC) CDX-014 will be presented at the American Association of Cancer Res
Read more →CLDXCelldex Reports Fiscal 2013 Business/Financial Results and Outlines 2014 Strategy
HAMPTON, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2013 and outlined the Company's major clinical development goals for 2014. "This past yea
Read more →CLDXCelldex to Report Fourth Quarter and Fiscal 2013 Business/Financial Results and Host 2014 Strategy Conference Call
HAMPTON, N.J., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year end 2013 financial results on Monday, March 3, 2014 before the U.S. financial markets open. Celldex executives will host a conference call at 8:30 a.m. E
Read more →CLDXCelldex Announces Upcoming Presentation at the 2014 Leerink Global Healthcare Conference
HAMPTON, N.J., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Senior Vice President and Chief Medical Officer, are scheduled to present a corporate overvie
Read more →CLDXCelldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at ASH 2013
HAMPTON, N.J., Dec. 10, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today positive results from a preclinical combination study of CDX-301 (FMS-like tyrosine kinase-3 ligand or Flt3L) and Mozobil (Plerixafor injection, formerly AMD3100) demonstrati
Read more →CLDXCelldex Therapeutics Prices Public Offering of Common Stock
HAMPTON, N.J., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 7,000,000 shares of its common stock, offered at a price to the public of $24.50 per share for an aggregate offering of $171,
Read more →CLDXSarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics , Inc. (781) 433-3161 scavanaugh@celldex.com Celldex Therapeutics Prices Public Offering of Common Stock HAMPTON, NJ (
Vice President of Investor Relations & Celldex Therapeutics, Inc. scavanaugh@celldex.com Celldex Therapeutics Prices Public Offering of Common Stock HAMPTON, NJ (December 4, 2013): Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced the pricing of an underwritten public
Read more →CLDXCelldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
HAMPTON, N.J., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it has launched a randomized study (METRIC) of Glembatumumab vedotin (CDX-011) in patients with metastatic triple negative breast cancers that over-express glycoprotein N
Read more →CLDXCelldex Announces Upcoming Presentation at the Deutsche Bank 2013 BioFEST
HAMPTON, N.J., Nov. 27, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tom Davis, M.D., Senior Vice President and Chief Medical Officer are scheduled to present at the Deutsche Ban
Read more →CLDXRindopepimut Society for Neuro-Oncology (SNO) 2014 Update
Median, Years (95% CI) 2-year rate 3-year rate 4-year rate 5-year rate Phase II Rindopepimut Studies, Pooled (n=105) 2.1 (1.8, 2.4) 51% 30% 18%* 14%* Matched historical control (n=17)** 1.3 (0.9, 1.7) 6% 6% 0% 0% HR (95% CI): 0.31 (0.19, 0.53) p < 0.0001 *ACT III OS rate: 4-years
Read more →CLDXSarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics , Inc. (781) 433-3161 scavanaugh@celldex.com Celldex Therapeutics Rindopepimut Demonstrates Promising Clinical Activity in P
Vice President of Investor Relations & Celldex Therapeutics, Inc. scavanaugh@celldex.com Celldex Therapeutics Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO Strong interim survival trend (12.0 vs 7.9 mon
Read more →CLDXCelldex Therapeutics' Rindopepimut Demonstrates Promising Clinical Activity in Patients with EGFRvIII-positive Recurrent Glioblastoma at SNO
Strong interim survival trend (12.0 vs 7.9 months) emerging in ongoing bevacizumab naive randomized cohort; 5.6 month median OS (48% > 6 months) in bevacizumab refractory single-arm cohort; robust anti-tumor immune responses were generated among heavily pre-treated patients with
Read more →CLDXCelldex Therapeutics Announces Publication of Preliminary Data from the Phase 2 ReACT Study to be Presented at the 18th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)
PHILLIPSBURG, N.J., Nov. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that preliminary data from "ReACT: a Phase 2 Study of Rindopepimut Vaccine (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma", was published in the 2013 abstract suppl
Read more →CLDXCelldex Reports Third Quarter 2013 Financial Results
PHILLIPSBURG, N.J., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported financial results for the third quarter ended September 30, 2013. Celldex reported a net loss of $23.1 million, or $0.29 per share, for the third quarter of 2013 compared
Read more →CLDXCelldex Therapeutics' CDX-1127 Well Tolerated and Demonstrates Anti-Tumor Activity in Phase 1 Dose-Escalation Study
Very favorable safety profile; no evidence of immune related toxicities Three patients with significant tumor shrinkage, including an ongoing CR in Hodgkin disease Eight patients with stable disease or better; PFS range of 3.0 to 14+ months Immune monitoring data in patients c
Read more →CLDXCelldex Therapeutics Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer and Society of Neuro-Oncology Annual Meetings
PHILLIPSBURG, N.J., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that data from two of its clinical programs, the Phase 1 dose-escalation CDX-1127 study and the Phase 2 recurrent rindopepimut study, will be presented at two upcoming m
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation at the Leerink Swann Rare Disease Roundtable
PHILLIPSBURG, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer, will present at the Leerink Swann
Read more →CLDXCelldex Announces Expansion of Phase 2 ReACT Study in Recurrent Glioblastoma
PHILLIPSBURG, N.J., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) Celldex Therapeutics recently completed enrollment in an initial cohort (n=25) of Avastin (bevacizumab) refractory patients in the Company's ongoing ReACT study of rindopepimut in EGFRv
Read more →CLDXCelldex Reports Second Quarter 2013 Financial Results
PHILLIPSBURG, N.J., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported financial results for the second quarter ended June 30, 2013. Celldex reported a net loss of $19.0 million, or $0.24 per share, for the second quarter of 2013 compared to
Read more →CLDXCelldex Therapeutics Announces Issuance of Seminal Patent for CD27 Agonists
PHILLIPSBURG, N.J., July 10, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No: 8,481,029 entitled "Human immune therapies using a CD27 agonist alone or in combinati
Read more →CLDXCelldex Therapeutics Initiates Pilot Study in Dense Deposit Disease
PHILLIPSBURG, N.J., July 1, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported that the first patient has been dosed in the Company's pilot study of CDX-1135 (a soluble form of human complement receptor type 1) in dense deposit disease (DDD). DDD is
Read more →CLDXCelldex Therapeutics to Present at Two Upcoming Investor Conferences
NEEDHAM, Mass., May 22, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, will present a corporate overview at the Deutsche Bank 38th Annual Healthcare Conference in Boston on May 29, 201
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation at the Credit Suisse 2013 Antibody Day
NEEDHAM, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Tibor Keler, Ph.D., Senior Vice President and Chief Scientific Officer, will present an overview of the Company's antibody technology and pipeline at the Credit Suisse An
Read more →CLDXSarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics , Inc. (781) 433-3161 scavanaugh@celldextherapeutics.com CELLDEX REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS NEEDHAM, MA (
Vice President of Investor Relations & Celldex Therapeutics, Inc. scavanaugh@celldextherapeutics.com CELLDEX REPORTS FIRST QUARTER 2013 FINANCIAL RESULTS NEEDHAM, MA (May 2, 2013): Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarte
Read more →CLDXCelldex Reports First Quarter 2013 Financial Results
NEEDHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported financial results for the first quarter ended March 31, 2013. Celldex reported a net loss of $17.3 million, or $0.23 per share, for the first quarter of 2013 compared to a net
Read more →CLDXCelldex Presents CDX-1127 In Vitro Human Data Consistent With Strong Potency and Safety Profile at AACR 2013
--Results Directly Complement Ongoing Clinical Development-- NEEDHAM, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported the results of an in vitro study analyzing the activation of human T cells with CDX-1127. CDX-1127 is a monoclon
Read more →CLDXManagement to Host Conference Call to Discuss Results and Provide 2013 Outlook Today, Thursday, March 7, at 8:30 a.m.
FOR IMMEDIATE RELEASE/March 7, 2013 Vice President of Investor Relations & Celldex Therapeutics, Inc. scavanaugh@celldextherapeutics.com CELLDEX REPORTS FOURTH QUARTER AND FISCAL 2012 FINANCIAL RESULTS - Management to Host Conference Call to Discuss Results and Provide 2013
Read more →CLDXCelldex Reports Fourth Quarter and Fiscal 2012 Financial Results
NEEDHAM, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today reported financial results for the fourth quarter and the year ended December 31, 2012. Celldex reported a net loss of $16.8 million, or ($0.27) per share, for the fourth quarter of 2
Read more →CLDXCelldex Therapeutics to Report Fourth Quarter and Fiscal 2012 Financial Results and Host Corporate 2013 Strategic Outlook Call
NEEDHAM, Mass., Feb. 28, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year end 2012 financial results on Thursday, March 7, 2013 before the U.S. financial markets open. Celldex executives will host a conference call at 8:30 a.m
Read more →CLDXCelldex Therapeutics Announces Upcoming Presentation at Leerink Swann Global Healthcare Conference 2013
NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Leerink Swann Global Healthcare Conference 2013 on Wednesday
Read more →CLDXCelldex Announces Upcoming Oral Presentation on CDX-301 at the American Society for Blood and Marrow Transplantation 2013 BMT Tandem Meetings
NEEDHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that Michael Yellin, MD, Vice President of Clinical Science, will present final results from a Phase 1 trial of CDX-301 (rhuFlt3L) in healthy volunteers in an oral presentat
Read more →CLDXCelldex Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common sto
Read more →CLDXCelldex Announces Pricing of $90 Million Public Offering of Common Stock
NEEDHAM, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price to the public of $7.50 per share for an aggregate offering of $90,
Read more →CLDXCelldex Announces $75,000,000 Proposed Public Offering of Common Stock
NEEDHAM, Mass., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it is offering $75,000,000 of its common stock in a proposed underwritten public offering. All of the shares in the offering will be sold by Celldex. The offering is sub
Read more →CLDXCorporate Presentation January 2013 Forward Looking Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than s
Yervoy CDX-1127 1st product with clinical/commercial validation CDX-1127: A Novel Immune Modulator Targeting CD27 CD27 is a co-stimulatory molecule on T cells and is over-expressed in certain lymphomas/leukemias CDX-1127 has 2 mechanisms of action: Immune activation Effector func
Read more →CLDXCelldex Reports Third Quarter 2012 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2012 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--November 1, 2012--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter ended September 30, 2012. Celldex reported a net loss of $15.0 million, or $0.25 pe
Read more →CLDXCelldex Reports Second Quarter 2012 Financial Results - Management to Host Conference Call Today at 8:30 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2012 Financial Results Management to Host Conference Call Today at 8:30 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--August 10, 2012--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the second quarter ended June 30,
Read more →CLDXAnthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Brad Miles Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. BMC Communications (781) 433-0771 (781) 433-0771 (646) 513-3125 IR@
Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Brad Miles Celldex Therapeutics, Inc. Celldex Therapeutics, Inc. BMC Communications (781) 433-0771 (781) 433-0771 (646) 513-3125 IR@celldextherapeutics.com bmiles@bmccommunications.com CELLD
Read more →CLDXCelldex Reports First Quarter 2012 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Reports First Quarter 2012 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--May 3, 2012--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2012. Celldex reported a net loss of $13.5 million, or $0.27 per share,
Read more →CLDXManagement to Host Conference Call to Discuss Results and Provide 2012 Outlook
FOR IMMEDIATE RELEASE/March 7, 2012 Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Brad Miles Celldex Therapeutics , Inc. Celldex Therapeutics , Inc. BMC Communications (781) 433-0771 (781) 433-0771 (917) 570-7340 IR@celldext
Read more →CLDXCelldex Prices Public Offering of Common Stock
FOR IMMEDIATE RELEASE/February 24, 2012 Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Brad Miles Celldex Therapeutics , Inc. Celldex Therapeutics , Inc. BMC Communications (781) 433-0771 (781) 433-0771 (212) 477-9007 x17 IR
Read more →CLDXCelldex Reports Third Quarter 2011 Financial Results - Company Preparing for Initiation of Rindopepimut Pivotal Phase 3 Study by Year-End - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2011 Financial Results Preparing for Initiation of Rindopepimut Pivotal Phase 3 Study by NEEDHAM, Mass.--(BUSINESS WIRE)--November 2, 2011--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine months e
Read more →CLDXCelldex Reports Second Quarter 2011 Financial Results and Announces Finalization of Rindopepimut Pivotal Program Design - Management to Host Conference Call Today at 8:30 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2011 Financial Results and Announces Finalization of Rindopepimut Pivotal Program Design Management to Host Conference Call Today at 8:30 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--August 3, 2011--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today
Read more →CLDXCelldex Expands Senior Management Team with Appointment of
FOR IMMEDIATE RELEASE/July 6, 2011 Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Brad Miles Celldex Therapeutics , Inc. Celldex Therapeutics , Inc. BMC Communications (781) 433-0771 (781) 433-0771 (212) 477-9007 x17 IR@celldext
Read more →CLDXCelldex Reports First Quarter 2011 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Reports First Quarter 2011 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--May 4, 2011--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2011. Celldex reported a net loss of $10.1 million, or $0.31 per share,
Read more →CLDXCelldex Reports Fourth Quarter and Fiscal 2010 Financial Results - Management to Host Conference Call to Discuss Results and Provide 2011 Outlook Today, Thursday, March 3, at 8:30 a.m. Eastern Time - NEEDHAM, Mass.--(BUS
Reports Fourth Quarter and Fiscal 2010 Financial Results Management to Host Conference Call to Discuss Results and Provide 2011 Outlook Today, Thursday, March 3, at 8:30 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--March 3, 2011--Celldex Therapeutics, Inc. (NASDAQ: CL
Read more →CLDXCelldex Reports Third Quarter 2010 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Third Quarter 2010 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--November 2, 2010--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per
Read more →CLDXCelldex Reports Second Quarter 2010 Financial Results - Management to Host Conference Call Today at 10:00 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Second Quarter 2010 Financial Results Management to Host Conference Call Today at 10:00 AM Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--August 4, 2010--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the second quarter ended June 30,
Read more →CLDXCelldex Reports First Quarter 2010 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Reports First Quarter 2010 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--May 4, 2010--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, f
Read more →CLDXCelldex Reports Fourth Quarter and Fiscal 2009 Financial Results - Management to Host Conference Call to Discuss Results and Provide 2010 Outlook Today, Thursday, March 4, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUS
Reports Fourth Quarter and Fiscal 2009 Financial Results Management to Host Conference Call to Discuss Results and Provide 2010 Outlook Today, Thursday, March 4, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--March 4, 2010--Celldex Therapeutics, Inc. (NASDAQ: CL
Read more →CLDXMillion Sublicense Income Payment from TopoTarget
FOR IMMEDIATE RELEASE/February 16, 2010 Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Matthew Driscoll Celldex Therapeutics , Inc. Celldex Therapeutics , Inc. BMC Communications Group (781) 433-0771 (781) 433-0771 (973) 271-6085
Read more →CLDXCelldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--November 4, 2009--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex
Read more →CLDXCelldex and CuraGen Stockholders
FOR IMMEDIATE RELEASE/September 30, 2009 Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Matthew Driscoll Celldex Therapeutics , Inc. Celldex Therapeutics , Inc. BMC Communications Group (781) 433-0771 (781) 433-0771 (973) 271-6085
Read more →CLDXCelldex Therapeutics Announces Appointment of Larry Ellberger as Chairman of the Board NEEDHAM, Mass.--(BUSINESS WIRE)
Therapeutics Announces Appointment of Larry Ellberger as Chairman of the NEEDHAM, Mass.--(BUSINESS WIRE)--September 4, 2009--Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Larry Ellberger has been appointed Chairman of the Board of Directors, effective Septemb
Read more →CLDXCelldex Reports Second Quarter and Six Month 2009 Financial Results - Conference Call Wednesday, August 5, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Second Quarter and Six Month 2009 Financial Results Conference Call Wednesday, August 5, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--August 5, 2009--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the second quarter and
Read more →CLDXASCO Abstract No. 2021 EMBARGOED UNTIL SATURDAY, MAY 30, 2009 at 8:00 a.m. EDT Pfizer and Celldex Therapeutics Present Update on CDX-110 (PF-04948568) Phase 2 Brain Cancer Studies at 45 th Annual ASCO Meeting - Updated f
ASCO Abstract No. 2021 EMBARGOED UNTIL SATURDAY, MAY 30, 2009 at 8:00 a.m. EDT Pfizer and Celldex Therapeutics Present Update on CDX-110 (PF-04948568) Phase 2 Brain Cancer Studies - Updated follow-up of time to progression and overall survival reported from Phase 2 clinical
Read more →CLDXCelldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation Conference call scheduled for Friday
Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation Conference call scheduled for Friday, May 29, 2009 at 8:30 AM ET Transaction adds 11 oncology-focused antibodies, including CR011, to expand Celldex s Pre
Read more →CLDXCelldex Reports First Quarter 2009 Financial Results - Conference Call Tuesday, May 5, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports First Quarter 2009 Financial Results Conference Call Tuesday, May 5, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--May 5, 2009--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2009. Cellde
Read more →CLDXCelldex Reports Fourth Quarter and Fiscal 2008 Financial Results - Conference Call Friday, February 27, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)
Reports Fourth Quarter and Fiscal 2008 Financial Results Conference Call Friday, February 27, at 9:00 a.m. Eastern Time - NEEDHAM, Mass.--(BUSINESS WIRE)--February 27, 2009--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the fourth quarter and
Read more →CLDXCELLDEX REPORTS THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS - Conference Call Wednesday, November 5, at 9:00 a.m. Eastern Time - NEEDHAM, MA (
CELLDEX REPORTS THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS - Conference Call Wednesday, November 5, at 9:00 a.m. Eastern Time - NEEDHAM, MA (November 5, Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended
Read more →CLDXAVANT Immunotherapeutics Announces Name
FOR IMMEDIATE RELEASE/September 29, Anthony S. Marucci Avery W. Catlin For Media: President and CEO Chief Financial Officer Dan Budwick AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. BMC Communications Group (781) 433-0771 (781) 433-0771 (973) 271-6085 i
Read more →CLDXAVANT Reports Second Quarter and Six Month Financial Results Conference Call Wednesday, August 6 at 9:00 a.m. Eastern Time NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported fin
Reports Second Quarter and Six Month Financial Results Call Wednesday, August 6 at 9:00 a.m. Eastern Time NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today reported financial results for the second quarter and six-month period ended June 30,
Read more →CLDXEMBARGOED UNTIL 10:15 AM CDT ON MONDAY, JUNE 2, 2008 Pfizer, Inc. Vanessa Aristede (212) 733-3784 BMC Communications Brad Miles (on-site) Dan Budwick (917) 570-7340 (212) 477-9007 x14 UPDATED CDX-110 DATA IN GLIOBLASTOMA
EMBARGOED UNTIL 10:15 AM CDT ON MONDAY, JUNE 2, 2008 Pfizer, Inc. Vanessa Aristede (212) 733-3784 BMC Communications Brad Miles (on-site) Dan Budwick (917) 570-7340 (212) 477-9007 x14 UPDATED CDX-110 DATA IN GLIOBLASTOMA MULTIFORME PRESENTED AT 44th ANNUAL ASCO ANNU
Read more →CLDXImmediate Release: April 16, 2008
Immediate Release: April 16, 2008 Pfizer Media Contact : AVANT Investor Contact: Shreya Jani Una Ryan (212) 733-4889 President and CEO (781) 433-0771 Pfizer Investor Contact : Jennifer Davis Ronald C. Newbold (212) 733-0717 SVP, Business Development (908) 454-7120 x31
Read more →CLDXAVANT ANNOUNCES COMPLETED MERGER
FOR IMMEDIATE RELEASE/March 7, 2008 Una S. Ryan, Ph.D. Avery W. Catlin For Media: President and CEO Chief Financial Officer Joan Kureczka AVANT Immunotherapeutics, Inc. AVANT Immunotherapeutics, Inc. Kureczka/Martin Associates (781) 433-0771 (781) 433-0771 (415) 821-2413
Read more →CLDXAVANT Reports Fourth Quarter and Fiscal 2007 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the fourth quarter and year ended
Reports Fourth Quarter and Fiscal 2007 Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the fourth quarter and year ended December 31, 2007. AVANT reported a net loss of $5.3 million, or $0.0
Read more →CLDXAVANT APPEALS DELISTING NOTIFICATION FROM NASDAQ NEEDHAM, MA (
AVANT APPEALS DELISTING NOTIFICATION FROM MA (January 9, 2008): AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that on January 8, 2008 it received a letter from The NASDAQ Stock Market indicating that AVANT had failed to regain compliance with the Nasdaq Capita
Read more →CLDXAVANT Immunotherapeutics Reports Third Quarter and Nine-Month Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
AVANT Immunotherapeutics Reports Third Quarter and Nine-Month Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--Oct. 31, 2007--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the third quarter and first nine-month period of fiscal year 2007.
Read more →CLDXAVANT Immunotherapeutics, Inc. and Celldex Therapeutics Schedule Joint Teleconference for Monday
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics Schedule Joint Teleconference for Monday, October 22, 2007 at 9:00 AM MA and Phillipsburg, NJ, October 22, 2007 AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) and Celldex Therapeutics, Inc., a privately-held company, anno
Read more →CLDXAVANT Receives Approval to Transfer Securities to the NASDAQ Capital Market NEEDHAM, Mass.--(BUSINESS WIRE)
AVANT Receives Approval to Transfer Securities to the NASDAQ Capital Market NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 30, 2007--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that on August 29, 2007 it received a letter from The NASDAQ Stock Market stating that AV
Read more →CLDXAVANT Receives NASDAQ Deficiency Notice Relating to Market Value NEEDHAM, Mass.--(BUSINESS WIRE)
AVANT Receives NASDAQ Deficiency Notice Relating to Market Value NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 21, 2007--AVANT Immunotherapeutics (Nasdaq: AVAN) announced today that on August 15, 2007 it received a letter from The NASDAQ Stock Market stating that for the last 10 cons
Read more →CLDXAVANT Immunotherapeutics Reports Second Quarter and Six-Month Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)
AVANT Immunotherapeutics Reports Second Quarter and Six-Month Financial Results NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2007--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the second quarter and first six-month period of fiscal year 2007
Read more →CLDXAVANT Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price NEEDHAM, Mass.--(BUSINESS WIRE)
AVANT Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price NEEDHAM, Mass.--(BUSINESS WIRE)--July 10, 2007--AVANT Immunotherapeutics (Nasdaq: AVAN) announced today that on July 6, 2007 it received a letter from The NASDAQ Stock Market stating that for the last 30 co
Read more →Competitive Position
How CLDX ranks across every disease it competes inCompetitive Position is a premium feature
See how CLDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial